Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [09/02/2025 12:42 PDT] Relmada Therapeutics, Inc. (NASDAQ:RLMD), Up By 100% ($1.12) From $1.12 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [09/02/2025 06:09 PDT] RLMD Expected to Trade Up After Bullish Patterns Develop
• [08/28/2025 11:07 PDT] Relmada Therapeutics, Inc. (NASDAQ:RLMD), Up By 100% ($0.57) From $0.568 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/14/2025 07:16 PDT] RLMD Expected to Trade Up After Bullish Patterns Develop
• [07/14/2025 07:27 PDT] RLMD Expected to Trade Up After Bullish Patterns Develop